SL Science Submits FDA Orphan Drug Request For VDelta2+ Cell Therapy In Glioblastomas; Stock Up

SL Science Holding (SLBT) submitted an Orphan Drug Designation request to the FDA for its VDelta2+ Gamma Delta T (GDT) cell therapy targeting glioblastoma multiforme. The filing is a potentially positive regulatory step that could support future development and incentives, but it does not by itself change efficacy/approval timelines.

Analysis

SL Science Holding (SLBT) submitted an Orphan Drug Designation request to the FDA for its VDelta2+ Gamma Delta T (GDT) cell therapy targeting glioblastoma multiforme. The filing is a potentially positive regulatory step that could support future development and incentives, but it does not by itself change efficacy/approval timelines.